Biodesix Inc
NASDAQ:BDSX
Net Margin
Biodesix Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Biodesix Inc
NASDAQ:BDSX
|
65.3m USD |
-54%
|
|
| US |
|
Cigna Corp
NYSE:CI
|
80B USD |
2%
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
67.9B EUR |
2%
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
76.6B USD |
1%
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
26.5B EUR |
3%
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.7B EUR |
2%
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.2B USD |
6%
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
18.9B USD |
9%
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
13.2B EUR |
3%
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
12.9B USD |
9%
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
11.2B USD |
7%
|
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Biodesix Inc's most recent financial statements, the company has Net Margin of -54.3%.
You don't have any saved screeners yet